Clinical Trial

CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A phase II study to evaluate safety, tolerability and efficacy of CS0159 in patients with PBC (Primary Biliary Cholangitis).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-06-07; most recent amendment 2026-03-12.
Status change: Recruiting → Active, Not Recruiting 2024-11-18
Status change: Not Yet Recruiting → Recruiting 2023-08-31
Trial Details
NCT Number NCT05896124
Lead Sponsor Cascade Pharmaceuticals, Inc
Conditions Primary Biliary Cholangitis (PBC)
Enrollment 75 participants
Start Date 2023-08-07
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-03-15 (estimated)
Updated on ClinicalTrials.gov 2026-03-13